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Abstract
Background: Randomised controlled trials (RCTs) are widely accepted as the preferred study design for evaluating
healthcare interventions. When the sample size is determined, a (target) difference is typically specified that the RCT is
designed to detect. This provides reassurance that the study will be informative, i.e., should such a difference exist, it is likely
to be detected with the required statistical precision. The aim of this review was to identify potential methods for specifying
the target difference in an RCT sample size calculation.
Methods and Findings: A comprehensive systematic review of medical and non-medical literature was carried out for
methods that could be used to specify the target difference for an RCT sample size calculation. The databases searched
were MEDLINE, MEDLINE In-Process, EMBASE, the Cochrane Central Register of Controlled Trials, the Cochrane Methodology
Register, PsycINFO, Science Citation Index, EconLit, the Education Resources Information Center (ERIC), and Scopus (for in-
press publications); the search period was from 1966 or the earliest date covered, to between November 2010 and January
2011. Additionally, textbooks addressing the methodology of clinical trials and International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) tripartite guidelines for clinical trials
were also consulted. A narrative synthesis of methods was produced. Studies that described a method that could be used
for specifying an important and/or realistic difference were included. The search identified 11,485 potentially relevant
articles from the databases searched. Of these, 1,434 were selected for full-text assessment, and a further nine were
identified from other sources. Fifteen clinical trial textbooks and the ICH tripartite guidelines were also reviewed. In total,
777 studies were included, and within them, seven methods were identified—anchor, distribution, health economic,
opinion-seeking, pilot study, review of the evidence base, and standardised effect size.
Conclusions: A variety of methods are available that researchers can use for specifying the target difference in an RCT
sample size calculation. Appropriate methods may vary depending on the aim (e.g., specifying an important difference
versus a realistic difference), context (e.g., research question and availability of data), and underlying framework adopted
(e.g., Bayesian versus conventional statistical approach). Guidance on the use of each method is given. No single method
provides a perfect solution for all contexts.
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Introduction
A randomised controlled trial (RCT) is widely regarded as the
preferred study design for comparing the effectiveness of health
interventions [1]. Central to the design and validity of an RCT is a
calculation of the number of participants needed: the sample size.
This provides reassurance that the study will be informative. Using
the Neyman-Pearson method (a conventional approach to sample
size calculation), a (target) difference that the RCT is designed to
detect is typically specified.
Selecting an appropriate target difference is critical. If too small
a target difference is estimated, the trial may be a wasteful and an
unethical use of data and resources. If too large a target difference
is hypothesized, there is a risk that a clinically relevant difference
will be overlooked because the study is too small. Both extremes
could therefore have a detrimental impact on decision-making [2].
Additionally, through its impact on sample size, the choice of
target difference has substantial implications in terms of study
conduct and associated cost.
However, unlike the statistical considerations involved in sample
size calculation, research on how to specify the target difference
has been greatly neglected, with no substantive guidance available
[3,4]. While a variety of potential approaches have been proposed,
such as specifying what an important difference would be (e.g., the
‘‘minimal clinically important difference’’) or what a realistic
difference would be given the results of previous studies, the
current state of the evidence base is unclear. Although some
reviews of different types of methods have been conducted [2,5],
there is still a need for a comprehensive review of available
methods. The aim of this systematic review was to identify
potential methods for specifying the target difference in an RCT
sample size calculation, whether addressing an important differ-
ence (a difference viewed as important by a relevant stakeholder
group [e.g., clinicians]) and/or realistic difference (a difference
that can be considered to be realistic given the interventions to be
evaluated). The methods are described, and guidance offered on
their use.
Methods
A comprehensive search of both biomedical and selected non-
biomedical databases was undertaken. Search strategies and
databases searched were informed by preliminary scoping work.
The final databases searched were MEDLINE, MEDLINE In-
Process, EMBASE, the Cochrane Central Register of Controlled
Trials, the Cochrane Methodology Register, PsycINFO, Science
Citation Index, EconLit, Education Resources Information Center
(ERIC), and Scopus (for in-press publications) from 1966 or
earliest date coverage; the searches were undertaken between
November 2010 and January 2011. Given the magnitude of the
literature identified by this initial search and the belief that
updating the search would not lead to additional approaches of
specifying the target difference, an update of this search was not
carried out. There was no language restriction. It was anticipated
that reporting of methods in the titles and abstracts would be of
variable quality and that therefore a reliance on indexing and text
word searching would be inadvisable. Consequently, several other
methods were used to complement the electronic searching and
included checking of reference lists, citation searching for key
articles using Scopus and Web of Science, and contacting experts
in the field. The protocol and details of the search strategies used
are available in Protocol S1 and Search Strategy S1.
Additionally, textbooks covering methodological aspects of
clinical trials were consulted. These textbooks were identified by
searching the integrated catalogue of the British Library and the
catalogues (for the most recent 5 y) of several prominent publishers
of statistical texts. The project steering group was also asked to
suggest key clinical trial textbooks that could be assessed. Because
of the nature of the review, ethical approval was unnecessary.
To be included in this review, each study had to report a formal
method that had been used or could be used to specify a target
difference. Any study design for original research was eligible,
provided its assessment was based on at least one outcome of
relevance to a clinical trial. Studies were excluded only if they were
reviews, failed to report a method for specifying a target difference,
reported only on statistical sample size considerations rather than
clinical relevance, or assessed an outcome measure (e.g., number
needed to treat) without reference to how a difference could be
determined.
Potentially relevant titles and abstracts were screened by either
or both of two reviewers (J. H. or T. G.), with any uncertainties or
disagreements discussed with a third party (J. A. C.). Full-text
articles were obtained for the titles and abstracts identified as
potentially relevant. These were provisionally categorised accord-
ing to method of specifying the target difference (if detailed in the
abstract). One of four reviewers (J. H., T. G., K. H., or T. E. A.)
screened the full-text articles and extracted information, after
having screened and extracted information from a practice sample
of articles and compared results to ensure consistency in the
screening process. Where there was uncertainty regarding whether
or not a study should be included for data extraction, the opinion
of a third party (J. A. C.) was sought, and the study discussed until
consensus was reached.
Data were extracted on the methodological details and any
noteworthy features such as unique variations not found in other
studies reporting the same method. Specific information relevant
to each particular method was recorded, and no generic data
extraction form was used across all methods. It was felt that a
generic data extraction form that included all fields of relevance to
all methods would be too cumbersome, because the methods
varied in conception and implementation.
Narrative descriptions of each method were produced, summa-
rising the key characteristics based on extracted data on the
similarities and differences in each application of the same
method, frequency with which each variant of the method was
used, and strengths and weaknesses of the method, either
identified by the review team as potentially important, or extracted
from study authors’ own points about the strengths and limitations
of their method (or methods) as reported in the articles. Methods
were assessed according to criteria developed by the steering group
prior to undertaking the evidence synthesis; the criteria covered
the validity, implementation, statistical properties, and applicabil-
ity of each method. The initial assessment was carried out by J. A.
C. and revised by the steering group.
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Results
We identified 11,485 potentially relevant studies from the
databases searched. The number of studies found within each
database is detailed in Figure 1 (PRISMA flow diagram), showing
the number of studies for each method.
Of the potentially relevant studies identified, 1,434 were selected
for full-text assessment; a further nine were identified from other
sources. Fifteen clinical trial textbooks and the International
Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use tripartite guide-
lines were also reviewed, though none identified a method that had
not already been identified from the journal database searches. In
total, 777 studies were included. Seven methods were identified—
anchor, distribution, health economic, opinion-seeking, pilot study,
review of the evidence base, and standardised effect size (SES).
Descriptions of these methods are provided in Box 1. No methods
were identified by this review beyond those already known to the
reviewers. The anchor, distribution, opinion-seeking, review of the
evidence base, and SES methods were used in studies in varied
clinical and treatment areas, but predominantly in those pertaining
to chronic diseases. Although the number of included studies for
both the health economic and pilot study methods was much
smaller, real or hypothetical trial examples covered pharmacolog-
ical and non-pharmacological treatments for both acute and
chronic conditions.
Substantial variation between studies was found in the way the
seven methods were implemented. In addition, some studies used
several methods, although the combinations used varied, as did the
extent to which results were triangulated. The anchor method was
Figure 1. PRISMA flow diagram. *For a breakdown of studies that used more than one method in combination, please see Table 1. Central,
Cochrane Central Register of Controlled Trials; CMR, Cochrane Methodology Register; ERIC, Education Resources Information Center; SCI, Science
Citation Index.
doi:10.1371/journal.pmed.1001645.g001
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the most popular, used by 447 studies, of which 194 (43%) used it
in combination with another method. The distribution method
was used by 324 studies, of which 153 (47%) used it alongside
another method. Eighty studies used an opinion-seeking method,
of which 20 (25%) also used additional methods. Twenty-seven
studies used a review of the evidence base method, of which five
(19%) also used another method. Six studies used a pilot study
method, of which one (17%) also used another method. The SES
method was used by 166 studies, of which 129 (78%) also used
another method. Thirteen studies used a health economic method.
For all methods used in combination with others, Table 1
provides a breakdown of the variety of combinations identified and
their frequency. The main variations identified from the systematic
review for each of the methods are described in Table 2, and are
further described in the text below. A brief summary of the
literature for each method is given below and also of studies that
used a combination of methods. Table 3 contains an assessment of
the value of the individual methods. Table 4 contains examples
and key implementation points for the use of each method.
Anchor Method
Implementation of the anchor method varied greatly [6–37]. In
its most basic form, the anchor method evaluates the minimal
(clinically) important change in score for a particular instrument.
This is established by calculating the mean change score (post-
intervention minus pre-intervention) for that instrument, among a
group of patients for whom it is indicated—via another instrument
(the ‘‘anchor’’)—that a minimum clinically important change has
occurred. The anchor instrument, the number of available points
on the anchor instrument for response, and the corresponding
labelling varied between applications. The anchor instrument was
most often a subjective assessment of improvement (e.g., global
rating of change), though objective measures of improvement
could be used (e.g., a 15-letter change in visual acuity as measured
on the Snellen eye chart) [34]. The anchor instrument was usually
posed to patients alone [19,35], though in some cases the
clinicians’ views alone were used. Older studies tended to use a
15-point Likert scale for the anchor instrument, as suggested by
Jaeschke and colleagues [16]; more recent studies tended to use
five- or seven-point scales instead. Depending upon the study size
and/or clinical context, merging of multiple points on the scale
may be required. For example, if a seven-point scale has been used
but very few people rate themselves at the extremes of this scale (1
and 7), it may be possible to merge points 1 and 2 of the scale and
points 6 and 7. It should be noted that it may not always be
appropriate to do this, depending on the clinical question under
consideration.
Relative change can be incorporated by comparing those for
whom an important change was identified to another patient
subset (tested using the same instrument and anchor) who reported
no change over time. Another common variation is to consider the
percentage change score in the instrument under consideration
[33], rather than the absolute score change. Determination of
what constituted an important difference was sometimes based
Box 1. Methods for Specifying an Important and/or Realistic Difference
Methods for specifying an important difference
N Anchor: The outcome of interest can be ‘‘anchored’’ by
using either a patient’s or health professional’s judgement
to define an important difference. This may be achieved by
comparing a patient’s health before and after treatment
and then linking this change to participants judged to
have shown improvement/deterioration. Alternatively, a
more familiar outcome, for which patients or health
professionals more readily agree on what amount of
change constitutes an important difference, can be used.
Alternatively, a contrast between patients can be made to
determine a meaningful difference.
N Distribution: Approaches that determine a value based
upon distributional variation. A common approach is to
use a value that is larger than the inherent imprecision in
the measurement and therefore likely to represent a
minimal level for a meaningful difference.
N Health economic: Approaches that use principles of
economic evaluation. These typically include both resource
cost and health outcomes, and define a threshold value for
the cost of a unit of health effect that a decision-maker is
willing to pay, to estimate the overall net benefit of
treatment. The net benefit can be analysed in a frequentist
framework or take the form of a (typically Bayesian)
decision-theoretic value of information analysis.
N Standardised effect size: The magnitude of the effect
on a standardised scale defines the value of the difference.
For a continuous outcome, the standardised difference
(most commonly expressed as Cohen’s d ‘‘effect size’’) can
be used. Cohen’s cutoffs of 0.2, 0.5, and 0.8 for small,
medium, and large effects, respectively, are often used.
Thus a ‘‘medium’’ effect corresponds simply to a change in
the outcome of 0.5 SDs. Binary or survival (time-to-event)
outcome metrics (e.g., an odds, risk, or hazard ratio) can be
utilised in a similar manner, though no widely recognised
cutoffs exist. Cohen’s cutoffs approximate odds ratios of
1.44, 2.48, and 4.27, respectively. Corresponding risk ratio
values vary according to the control group event
proportion.
Methods for specifying a realistic difference
N Pilot study: A pilot (or preliminary) study may be carried
out where there is little evidence, or even experience, to
guide expectations and determine an appropriate target
difference for the trial. In a similar manner, a Phase 2 study
could be used to inform a Phase 3 study.
Methods for specifying an important and/or a
realistic difference
N Opinion-seeking: The target difference can be based
on opinions elicited from health professionals, patients,
or others. Possible approaches include forming a panel
of experts, surveying the membership of a professional
or patient body, or interviewing individuals. This
elicitation process can be explicitly framed within a trial
context.
N Review of evidence base: The target difference can be
derived using current evidence on the research question.
Ideally, this would be from a systematic review or meta-
analysis of RCTs. In the absence of randomised evidence,
evidence from observational studies could be used in a
similar manner. An alternative approach is to undertake a
review of studies in which an important difference was
determined.
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upon the use of methodology more typically used to assess
diagnostic accuracy, such as receiver operating characteristic
curves [6,11,20], or more complex statistical approaches. It is
worth noting that the anchor method was not always successful in
deriving values for an important difference; failure was usually due
to either practical or methodological difficulties [17,23].
A substantially different way of achieving an anchor-based
approach for specifying an important difference was proposed by
Redelmeier and colleagues [28]: in this study, other patients
formed a reference against which a patient could rate their own
health (or health improvement) [10,27–30]. Generalisability of the
resulting estimate of an important difference is a key concern. For
example, if the disease is chronic and progressive, an important
change value from a newly diagnosed population may not apply to
a population with a far longer duration of illness [15,24,25,32,36].
A key consideration is how to decide on an appropriate cutoff
point for the anchor ‘‘transition’’ tool.
Participant biases, such as recall bias, are also potentially
problematic [13,14,21,22,25], as are response shift (whereby
patients’ perceptions of acceptable change alter during the course
of disease or treatment and become inconsistent) [37] and
gratitude factor or halo bias (whereby responses that are more
favourable than is realistic need to be taken into account) [31,35].
Another key choice is whether to consider improvement and
deterioration together or separately. If a Likert scale has been used
as the anchor, improvement and deterioration can be merged to
obtain one more general measure for ‘‘change’’ by ‘‘folding’’ the
scale at zero, though this assumes symmetry of effect, with ‘‘no
change’’ centred upon zero difference. This approach may be
unrealistic because of response biases and regression to the mean,
and is inappropriate if patients are likely to rate improvements in
their health differently from how they would rate deterioration
with the same condition. The method proposed by Redelmeier
and colleagues, where other participants act as the anchor, avoids
recall bias because all data can be collected at the same time,
though it may not be a universally appropriate method, as
participants might find it difficult to discuss particularly sensitive or
private health issues with others.
Distribution Method
Three distinct distribution approaches were found [38–56]:
measurement error, statistical test, and rule of thumb. The
measurement error approach determines a value that is larger
than the inherent imprecision in the measurement and that is
therefore likely to be consistently noticed by patients. The most
common approach for determining this value was based upon the
standard error of measurement (SEM). The SEM can be defined
in various ways, with different multiplicative factors suggested as
signifying a non-trivial (important) difference.
The most commonly used alternative to the SEM method
(although it can be thought of as an extension of this approach)
was the reliable change index proposed by Jacobson and Truax
[47], which incorporates confidence around the measurement
error. For the statistical test approach, a ‘‘minimal detectable
difference’’—the smallest difference that could be statistically
detected for a given sample size—is calculated. This is then used as
a guide for interpreting the presence of an ‘‘important’’ difference
in this study. The rule-of-thumb approach defines an important
difference based on the distribution of the outcome, such as using a
substantial fraction of the possible range without further justifica-
tion (e.g., 10 mm on a 100-mm visual analogue scale measuring
symptom severity being viewed as a substantial shift in outcome
response) [54].
Measurement error and rule-of-thumb approaches are widely
used, but do not translate straightforwardly to an RCT target
difference. This is because for measurement error approaches,
assessment is typically based on test–retest (within-person) data,
whereas many trials are of parallel group (between-person) design.
Additionally, measurement error is not suitable as the sole basis for
determining the importance of a particular target difference. More
Table 1. Use of multiple methods.
Methods Used in Combination
Number of
Studies
Anchor Distribution
Health
Economic Opinion-Seeking Pilot Study
Review of Evidence
Base
Standardised
Effect Size
! ! 70
! ! ! 63
! ! 46
! ! 13
! ! 8
! ! 3
! ! ! 2
! ! ! 2
! ! 2
! ! 1
! ! ! ! 1
! ! ! ! 1
! ! ! 1
! ! 1
! ! 1
! ! 1
doi:10.1371/journal.pmed.1001645.t001
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generally, the setting and timing of data collection may also be
important to the calculation of measurement error (e.g., results
may vary between pre- and post-treatment) [52]. The statistical
test approach cannot be used to specify a priori a target difference
in an RCT sample size calculation, as the observed precision of the
statistical test is conditional on the sample size. Rule-of-thumb
approaches are dependent upon the outcome having inherent
value (e.g., Glasgow coma scale), where a substantial fraction of a
unit change (e.g., one-third or one-half) can be viewed as
important.
Health Economic Method
The approaches included under the health economic method
typically involve defining a threshold value for the cost of a unit of
health effect that a decision-maker is willing to pay and using this
threshold to construct a ‘‘net benefit’’ that combines both resource
cost and health outcomes [57–65]. The extent to which data on
the differences in costs, benefits, and harms are used depends on
the decision and perspective adopted (e.g., treatment x is better
than treatment y when the net benefit for x is greater than that for
y, i.e., the incremental net benefit for x compared to y is positive)
[62]. The net benefit approach can be extended into a decision-
theoretic model in order to undertake a value of information
analysis [60,61,65], which seeks to address the value of removing
the current uncertainty regarding the choice of treatment. The
optimal sample size of a new study given the current evidence and
the decision faced can be calculated. The perspective of the
decision-making is critical, i.e., whether it is from the standpoint of
clinicians, patients, funders, policy-makers, or some combination.
More sophisticated modelling approaches can potentially allow
a comprehensive evaluation of the treatment decision and the
potential value of a new study, though they require strong
assumptions about, for example, different measurements of
effectiveness, harms, uptake, adherence, costs of interventions,
and the cost of new research. The increased complexity, along
with the gap between the input requirements of the more
sophisticated modelling approaches and the data that are typically
available, and the need to be explicit about the basis of synthesis of
all the evidence upfront, perhaps explains the limited use of these
modelling approaches in practice to date.
Opinion-Seeking Method
The opinion-seeking method determines a value (or a plausible
range of values) for the target difference, by asking one or more
individuals to state their view on what value or values for a
particular difference should be important and/or realistic [66–86].
The identified studies varied widely in whose opinion was sought
(e.g., patients, clinicians, or trialists), the method of selecting
individual experts (e.g., literature search, mailing list, or confer-
ence attendance), and the number of experts consulted. Other
variations included the method used to elicit values (e.g., interview
or survey), the complexity of the data elicited, and the method
used to consolidate results into an overall value or range of values
for the difference.
One advantage of the opinion-seeking method is the ease with
which it can be carried out (e.g., through a survey). However,
estimates will vary according to the specified population.
Additionally, different perspectives (e.g., patient versus health
professional) may lead to very different estimates of what is
important and/or realistic [73]. Also, the views of approached
individuals may not necessarily be representative of the wider
community. Furthermore, some methods for eliciting opinions
have feasibility constraints (e.g., face-to-face methods), but
alternative approaches for capturing the views of a larger number
of experts require careful planning or may be subject to low
response rates or partial responses [77].
Pilot Study Method
A small number of studies used a pilot study method to
determine a relevant value for the target difference [87–90]. A
pilot study can be defined as running the intended study in
miniature prior to conducting the actual trial, to guide expecta-
tions on an appropriate value for the target difference. The
simplest approach is to use the observed effect in the pilot study as
the target difference in an RCT. More sophisticated approaches
account for imprecision in the estimate from the pilot study and/
or use the pilot study to estimate only the standard deviation (SD)
(or control group event proportion) and not the target difference.
However, there are practical difficulties in conducting a pilot
study that may limit the relevance of results [87], most notably the
inherent uncertainty in results due to the small study sample size,
rendering the effect size imprecise and unreliable. Additionally, a
pilot study can address only a realistic difference and does not
inform what an important difference would be. Finally, it is worth
noting that an internal pilot study, using the initial recruits within a
larger study, cannot be used to pre-specify the target difference,
though it could inform an adaptive update [90]. Notwithstanding
the above critique, a pilot study can have a valuable role in
addressing feasibility issues (e.g., recruitment challenges) that may
need to be considered in a larger trial [89]. Pilot studies are most
useful when they can be readily and quickly conducted. While few
studies addressed using a pilot study to inform the specification of
the target difference, trialists may use pilot studies to help
determine the target difference without reporting this formally in
trial reports.
Review of the Evidence Base Method
Implementation of the review of the evidence base method
varied regarding what studies and results were considered as part
of the review and how the findings of different studies were
combined [91–103]. The most common approach involved
implementing a pre-specified strategy for reviewing the evidence
base for either a particular instrument or variety of instruments to
identify an important difference. Alternatively, pre-existing studies
for a specific research question may be used (e.g., using the pooled
estimate of a meta-analysis) to determine the target difference
[100]. Extending this general approach, Sutton and colleagues
[101] derived a distribution for the effect of treatment from the
meta-analysis, from which they then simulated the effect of a
‘‘new’’ study; the result of this study was added to the existing
meta-analysis data, which were then re-analysed. Implicitly this
adopts a realistic difference as the basis for the target difference.
Reviewing the existing evidence base is valuable as it provides a
rationale for choosing an important and/or realistic target
difference. It is likely that this general approach is often informally
used, though few have addressed how it should be formally done.
However, estimates identified from existing evidence may not
necessarily be appropriate for the population being considered for
the trial, so the generalisability of the available studies and
susceptibility to bias should be considered. For reviews of studies
that identified an important difference, the methods used in each
of the individual studies to determine that difference are subject to
the practical issues mentioned here for that method (e.g., the
anchor method). Imprecision of the estimate is also an important
consideration, and publication bias may also be an issue if reviews
of the evidence base consider only published data. If a meta-
analysis of previous results is used to determine a sample size, then
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additional evidence published after the search used in the meta-
analysis was conducted may necessitate updating the sample size.
Standardised Effect Size Method
This method is commonly used to determine the importance of
a difference in an outcome when set in comparison to other
possible effect sizes upon a standardised scale [88,104–116].
Overwhelmingly, studies used the guidelines suggested by Cohen
[106] for the Cohen’s d metric, i.e., 0.2, 0.5, and 0.8 for small,
medium, and large effects, respectively, in the context of a
continuous outcome. Other SES metrics exist for continuous (e.g.,
Dunlap’s d), binary (e.g., odds ratio), and survival (hazard ratio)
outcomes [106,111,116]. Most of the literature relates to within-
group SESs for a continuous outcome. The SD used should reflect
the anticipated RCT population as far as possible.
The main benefit of using a SES method is that it can be readily
calculated and compared across different outcomes, conditions,
studies, settings, and people; all differences are translated into a
common metric. It is also easy to calculate the SES from existing
evidence if studies have reported sufficient information. The
Cohen guidelines for small, medium, and large effects can be
converted into equivalent values for other binary metrics (e.g.,
1.44, 2.48, and 4.27, respectively, for odds ratio) [105]. As noted
above, SES metrics are commonly used for binary (e.g., odds ratio
or risk ratio) and survival outcomes (e.g., hazard ratio) in medical
research [111], and a similar approach can be readily adopted for
such outcomes. However, no equivalent guideline values are in
widespread use. Informally, a doubling or halving of a ratio is
sometimes seen as a marker of a large relative effect [109].
It is important to note that SES values are not uniquely defined,
and different combinations of values on the original scale can
produce the same SES value. For the standard Cohen’s d statistic,
different combinations of mean and SD values produce the same
SES estimate. For example, a mean (SD) of 5 (10) and 2 (4) both
give a standardised effect of 0.5SD. As a consequence, specifying
the target difference as a SES alone, though sufficient in terms of
sample size calculation, can be viewed as insufficient in that it does
not actually define the target difference for the outcome measure
of interest. A limitation of the SES is the difficulty in determining
why different effect sizes are seen in different studies: for example,
whether these differences are due to differences in the outcome
measure, intervention, settings, or participants in the studies, or
study methodology.
Combining Methods
The vast majority of studies that combined methods used two or
three of the anchor, distribution, and SES methods. Studies that
used multiple methods were not always clear in describing whether
and how results were triangulated, and for certain combinations
the result of one method seemed to be considered of greater value
than the result of another method (i.e., as if a primary and
supplementary method had been selected). For example, values
that were found using the anchor method were often chosen over
effect size results or distribution-based estimates [117]. Alterna-
tively, the most conservative value was chosen, regardless of the
comparative robustness of the methods used [118]. In cases where
the results of the different methods were similar, triangulation of
the results was straightforward [119].
Discussion
This comprehensive systematic review summarizes approaches
for specifying the target difference in a RCT sample size
calculation. Of the seven identified methods, the anchor,
distribution, and SES methods were most widely used. There
are several reasons for the popularity of these methods, including
ease of use, usefulness in studies validating quality of life
instruments, and simplicity of calculation of distribution and
SES estimates alongside the anchor method. While most studies
adopted (though typically implicitly) the conventional Neyman-
Pearson statistical framework, some of the methods (i.e., health
economic and opinion-seeking) particularly suit a Bayesian
framework.
No further methods were identified by this review beyond the
seven methods pre-identified from a scoping search. However,
substantial variations in implementation were noted, even for
relatively simple approaches such as the anchor method, and
many studies used multiple methods. Most studies focused on
continuous outcomes, although other outcome types were
considered using opinion-seeking and evidence base review. While
the methods could in principle be used for any type of RCT, they
are most relevant to the design of Phase 3, or ‘‘definitive’’, trials.
A number of key issues were common across the methods. First,
it is critical to decide whether the focus is to determine an
important and/or a realistic difference. Some methods can be used
for both (e.g., opinion-seeking), and some for only one or the other
(e.g., the anchor method to determine an important difference and
the pilot study method to determine a realistic difference).
Evaluating how the difference was determined and the context
of determining the target difference is important. Some approach-
es commonly used for specifying an important difference either
cannot be used for specifying a target difference (such as the
statistical test approach) or do not straightforwardly translate into
the typical RCT context (for example the measurement error
approach). The anchor, opinion-seeking, and health economic
methods explicitly involve judgment, and the perspective taken in
the study is a key consideration regarding their use. As a
consequence, these methods explicitly allow different perspectives
to be considered, and in particular enable the views of patients and
the public to be part of the decision-making process.
Some methodological issues are specific to particular methods.
For example, the necessity of choosing a cutoff point to define an
‘‘important’’ difference/change is specific to the anchor method.
This approach is a widely recognised part of the validation process
for new quality of life instruments, where the scale has no inherent
meaning without reference to an outside marker (i.e., anchor).
All three approaches of the distribution method—measurement
error, statistical test, and rule of thumb—have clear limitations,
the foremost being that they do not match the setting of a standard
RCT design (two parallel groups). The statistical test approach
cannot be used to specify a target difference, given that it is
essentially a rearranged sample size formula. The rule-of-thumb
approach is dependent upon the interpretability of the individual
scale.
The SES method was used in a substantial number of studies for
a continuous outcome, but was rarely reported for non-continuous
outcomes, despite informal use of such an approach probably
being widespread. No parallel for a binary outcome exists, though
odds ratio values approximately equivalent to Cohen’s d values
can be used. The validity of Cohen’s cutoffs is uncertain (despite
widespread usage), and some modifications to the original values
have been proposed [120,121].
The opinion-seeking method was often used with multiple
strategies involved in the process (e.g., questionnaires being sent to
experts using particular sampling methods, followed by an
additional conference being organised to discuss findings in more
detail). The Delphi technique for survey development and the
nominal group technique for face-to-face meetings are commonly
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used and are potentially useful for this type of research when
developing instruments. In terms of planning a trial, the opinion-
seeking method can be relatively easy to implement, but the
resulting usefulness of the estimated target difference may depend
on the robustness of the approach used to elicit opinions.
The health economic and pilot study methods were infrequently
reported as specific methods. For the health economic method,
this is likely due to the complexity of the method and/or the
resource-intensive procedures that are required to conduct the
theoretically more robust variants that have been developed. The
use of pilot studies to determine the target difference is
problematic and probably only useful for the control group event
proportion or SD, for a binary or continuous outcome,
respectively. Internal pilot studies may be incorporated into the
start of larger clinical trials, but are not useful for specifying the
target difference, though they could be used to revise the sample
size calculation. The review of the evidence base method can be
applied to identify both an important or realistic difference; a pilot
study addresses only a realistic difference. For both methods,
applicability to the anticipated study and the impact of statistical
uncertainty on estimates should be considered.
A review of the evidence base approach for a particular
outcome measurement or study population may be combined with
any of the other methods identified for establishing an important
difference. However, the number of studies reporting a formal
method for identifying an important difference using the existing
evidence was surprisingly small. It could be that there is wide
variation in the extent to which reviews of the existing evidence
base have been undertaken prospectively using a specific and
formal strategy.
Some methods can be readily used with others, potentially
increasing the robustness of their findings. The anchor and
distribution methods were often used together within the same
study, frequently also with the SES approach. Multiple methods
for specifying an important difference were used in some studies,
though the combinations varied, as did the extent to which results
were triangulated. The result of one method may validate the
result found using another method, but conflicting estimates
increase uncertainty over the estimate of an important difference.
Strengths and Limitations
To our knowledge, this review is the first comprehensive and
systematic search of all possible methods for specifying a target
difference. The search strategy was inclusive, robust, and logical;
however, this led to a large number of studies that did not report a
method for specifying an important and/or realistic difference.
Also, it is possible some studies were missed because of the lack of
standardised terminology. Finally, our search period ended in
January 2011, and another method not included in the seven
identified by this review may have been published since then,
although we believe this is unlikely. More likely is the use of new
variations in the implementation of existing methods.
Conclusions
A variety of methods are available that researchers can use for
specifying the target difference in an RCT sample size calculation.
Appropriate methods and implementation vary according to the
aim (e.g., specifying an important difference versus a realistic
difference), context (research question and availability of data), and
underlying framework adopted (Bayesian versus conventional
statistical approach). No single method provides a perfect solution
for all contexts. Some methods for specifying an important
difference (e.g., a statistical test–based approach) are inappropriate
in the RCT sample size context. Further research is required to
determine the best uses of some methods, particularly the health
economic, opinion-seeking, pilot study, and SES methods.
Prospective comparisons of methods in the context of RCT design
may also be useful. Better reporting of the basis upon which the
target difference was determined is needed [122].
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Editors’ Summary
Background. A clinical trial is a research study in which
human volunteers are randomized to receive a given
intervention or not, and outcomes are measured in both
groups to determine the effect of the intervention. Random-
ized controlled trials (RCTs) are widely accepted as the
preferred study design because by randomly assigning
participants to groups, any differences between the two
groups, other than the intervention under study, are due to
chance. To conduct a RCT, investigators calculate how many
patients they need to enroll to determine whether the
intervention is effective. The number of patients they need to
enroll depends on how effective the intervention is expected
to be, or would need to be in order to be clinically important.
The assumed difference between the two groups is the target
difference. A larger target difference generally means that
fewer patients need to be enrolled, relative to a smaller target
difference. The target difference and number of patients
enrolled contribute to the study’s statistical precision, and the
ability of the study to determine whether the intervention
is effective. Selecting an appropriate target difference is
important from both a scientific and ethical standpoint.
Why Was This Study Done? There are several ways to
determine an appropriate target difference. The authors
wanted to determine what methods for specifying the target
difference are available and when they can be used.
What Did the Researchers Do and Find? To identify
studies that used a method for determining an important
and/or realistic difference, the investigators systematically
surveyed the research literature. Two reviewers screened each
of the abstracts chosen, and a third reviewer was consulted if
necessary. The authors identified sevenmethods to determine
target differences. They evaluated the studies to establish
similarities and differences of each application. Points about
the strengths and limitations of the method and how
frequently the method was chosen were also noted.
What Do these Findings Mean? The study draws
attention to an understudied but important part of design-
ing a clinical trial. Enrolling the right number of patients is
very important—too few patients and the study may not be
able to answer the study question; too many and the study
will be more expensive and more difficult to conduct, and
will unnecessarily expose more patients to any study risks.
The target difference may also be helpful in interpreting the
results of the trial. The authors discuss the pros and cons of
different ways to calculate target differences and which
methods are best for which types of studies, to help inform
researchers designing such studies.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001645.
N Wikipedia has an entry on sample size determination that
discusses the factors that influence sample size calculation,
including the target difference and the statistical power of
a study (statistical power is the ability of a study to find a
difference between treatments when a true difference
exists). (Note: Wikipedia is a free online encyclopedia that
anyone can edit; available in several languages.)
N The University of Ottawa has an article that explains how
different factors influence the power of a study
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